Atyr Pharma Says Post-hoc Analysis Of Phase 1B/2A Study Of Efzofitimod For Pulmonary Sarcoidosis, Shows 7.7% Of Patients In The 3.0, 5.0 mg/kg Efzofitimod Group Relapsed Following Steroid Taper, Compared To 54.4% In Placebo, Efzofitimod 1.0 mg/kg
Benzinga Newsdesk - Sep 11, 2023, 8:10AM